StockData

Evotec vs Protagonist Therapeutics

EVO and PTGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EVO and PTGX compare

Protagonist Therapeutics grew revenue faster over the last twelve months (34.8% versus −1.1% for Evotec).

Protagonist Therapeutics scores higher on the StockData Score (12 against 4 for Evotec), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEVOPTGX
Size and price
Market cap–$8.1B
Share price$1.48$124.67
Change, 1 year−51.0%47.3%
Change, 5 years−93.8%275%
Beta (5Y)2.220.59
Employees4,553132
StockData Score
Total score412 (better)
Valuation score00
Growth score12 (better)
Performance score04 (better)
Health score36 (better)
Dividend score00
Valuation
P/E–121×
P/S–28.6×
P/B–9.6×
EV/EBITDA–122×
P/FCF–61.8×
FCF yield–1.6%
Fair value–$41.72
Margin of safety–−199%
Growth
Revenue growth (TTM)−1.1%34.8% (better)
Revenue growth, 5Y average9.5%10.0% (better)
Net income growth (TTM)–59.3%
EPS growth (TTM)–47.1%
Profitability
Gross margin14.5%–
Operating margin−7.1%20.7% (better)
Net margin–29.4%
FCF margin−10.4%46.3% (better)
Return on equity–11.0%
Return on invested capital−7.7%73.3% (better)
Financial health
Debt / equity0.10 (better)0.00
Net debt / EBITDA−7.79–
Current ratio2.0721.71 (better)
Altman Z-score–111.10
Piotroski F-score–5
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions1.8%117%
Held by insiders17.1%1.7%
Insider net buying, 12 months–−$95.0M
Superinvestors holding–1
Short interest, % of float–16.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.